Shield Therapeutics (STX) Reaches New 52-Week Low at $27.00
Shares of Shield Therapeutics PLC (LON:STX) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as GBX 27 ($0.37) and last traded at GBX 27 ($0.37), with a volume of 3379 shares changing hands. The stock had previously closed at GBX 27 ($0.37).
Several analysts have issued reports on the company. Peel Hunt reissued a “buy” rating and issued a GBX 220 ($3.04) price target on shares of Shield Therapeutics in a research note on Thursday, February 1st. Liberum Capital reissued an “under review” rating on shares of Shield Therapeutics in a research note on Monday, February 5th. Finally, FinnCap reissued a “buy” rating and issued a GBX 265 ($3.66) price target on shares of Shield Therapeutics in a research note on Tuesday, November 21st.
The company has a market capitalization of $7.79 and a PE ratio of -180.00.
About Shield Therapeutics
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. The Company’s product, Feraccru, is an oral treatment for iron deficiency anemia (IDA) in patients for whom intravenous iron or blood transfusions is needed.
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.